Sandra P. Susanibar-Adaniya, MD, MS
Hematology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West
Headshot of Sandra P. Susanibar-Adaniya, MD, MS
Penn Medicine Provider

About me

  • Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: National University of San Marcos
  • Residency: University of Arkansas for Medical Sciences
  • Fellowship: University of Pennsylvania Health System

What my patients think about me

Average Rating

381 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

January 2026
good talk
January 2026
she explained to me what might be wrong and what needed to be done to check if i would need future care
January 2026
my doctor is very knowledgeable and conveyed information to me clearly.
January 2026
very professional and knowledgeable

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Susanibar-Adaniya is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Heta Patel, Harper Hubbeling, Kyle L. Yu, Maribel Carpenter, Michael J. LaRiviere, John P. Plastaras, Adam D. Cohen, Shivani Kapur, Dan T Vogl, Adam J Waxman, Edward A Stadtmauer, Alfred L Garfall, Sandra Patricia Susanibar-AdaniyaCorresponding Author Outcomes of Radiation Integrated with T-cell-engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma , Blood advances: 2026


Ho M, Paruzzo L, Noll JH, Stella F, Devi P, Ndeupen S, Day YA, Chen GM, Cohen IJ, Ramirez-Fernandez A, Waxman A, Kapur S, Chen F, Xu R, Huff A, Jarocha D, Patel V, Bochi-Layec AC, Ramasubramanian R, Liu S, Bouvier R, de Souza VB, Patel H, Li Z, Carturan A, Michener P, Hopkins CR, Koucky O, Minehart J, Dimitri A, Nabar NR, Hasanali ZS, Ciccarelli BT, Hung P, Williams E, Bartoszek R, Lavorando M, Mohan S, Gonzalez VE, Porazzi P, Bhoj VG, Apostolidis SA, Vogl DT, Porter DL, Scholler J, Diorio C, Roche AM, Everett JK, Bushman FD, Nathanson KL, Stadtmauer EA, Susanibar-Adaniya SP, Garfall AL, Ruella M, Cohen AD, Fraietta JA. CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy. , Nature Medicine: 2026


Chen A, Smith KD, Wu RI, Ma K, Susanibar-Adaniya SP When sarcoidosis looks like myeloma: a diagnostic pitfall , Ann Intern Med Clin Cases, 5(1): 2026


Susanibar-Adaniya S, Derman BA, Cohen AD, Vogl DT, Richard S, Rossi A, Frigault MJ, Yee AJ, Dhakal B, Bar N Immune effector cell–associated enterocolitis post–BCMA-directed CAR T-cell therapy: Insights from a multicenter case series. , Blood Cancer Journal: 2026


Kyle L. Yu, Matthew Ho, Luca Paruzzo, Federico Stella, Heta Patel, Zainul S. Hasanali, Shivani Kapur, Adam J. Waxman, Dan T. Vogl, Edward A. Stadtmauer, Joseph A. Fraietta, Marco Ruella, Adam D. Cohen, Alfred L. Garfall & Sandra Susanibar-Adaniya Outcomes of relapse after teclistamab therapy in multiple myeloma , Blood Cancer Journal, 15(1): 2025


Beatrice M. Razzo; Shonali Midha; Andrew J. Portuguese ; Ariel F. Grajales-Cruz; Andre De Menezes Silva Corraes ; Patrick Costello; Yuxin Liu; Adam S. Sperling; Omar Nadeem ; Danai Dima; Rahul Banerjee; Andrew J.Rowan; Aimaz Afrough; Larry D. Anderson; Alex Lieberman-Cribbin; Gurbakhash Kaur; Anmol Goyal; Shebli Atrash; Christopher J. Ferreri; Peter M. Voorhees; Oren Pasvolsky; Hans C. Lee; Krina K. Patel; Kelley L. Julian; Peter A. Forsberg; Megan M. Herr; Saurabh Chhabra; Ricardo D. Parrondo; Yi Lin; Anna Chen; Sandra P. Susanibar-Adaniya; Jack Khouri; Shahzad Raza; Faiz Anwer; Mariola Vazquez-Martinez; Omar Castaneda Puglianini ; Douglas W. Sborov; James A. Davis ; Adriana Rossi; Leyla Shune; Jenny Bhurtel; Wei-Ting Hwang; Doris K. Hansen; Surbhi Sidana; Alfred L. Garfall;Shambavi Richard Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy Consortium , Blood Cancer Discovery: 2025


Luca Paruzzo, Khashayar Eshaghi, Guido Ghilardi, Abigail Doucette, Matthew Ho, Alberto Carturan, Dan T. Vogl, Adam J. Waxman, Shivani Kapur, Eugenio Fardella, Martina Pucillo, Antonio Imparato, Federico Stella, Puneeth Guruprasad, Vitor B. De Souza, Luke Maillie, Sofia Kaparis, Riemke Bouvier Bs, Adam D. Cohen, Jalpa A. Doshi, David L. Porter, Alfred L. Garfall, , Edward A. Stadtmauer, Carmen E. Guerra, Sandra P. Susanibar Adaniya, Marco Ruella Access and Outcomes of Racial and Ethnic Minority Populations Receiving Commercial Anti-BCMA CART for Myeloma , Blood Immunology & Cellular Therapy: 2025


Oren Pasvolsky, Danai Dima, Lei Feng, Wenli Dong, Tiffany Richards, James A Davis, Aimaz Afrough, Mariola Vazquez-Martinez, Aishwarya Sannareddy, Utkarsh Goel, Rahul Banerjee, Jack Khouri, Frances Cervoni, Mahmoud R Gaballa, Alex Lieberman-Cribbin, Masooma Shifa Rana, Kelley Julian, Christopher J Ferreri, Leyla Shune, Shaun DeJarnette, Evguenia Bhurtel, Sandra Susanibar Adaniya 13, Andrew Portuguese 2, Hitomi Hosoya 9, Lekha Mikkilineni 9, Gurbakhash Kaur, Adriana Rossi, Megan M Herr, Daniel Schrum, Chenyu Lin, Shahzad Raza, Yi Lin, Shonali Midha, Nadeem Omar, Shebli Atarsh, Joseph McGuirk, Douglas Sborov, Peter Voorhees, Faiz Anwer, Melissa Alsina, Ciara Freeman, Alfred L Garfall, Beatrice M Razzo, Surbhi Sidana, Andrew J Cowan, Larry D Anderson Jr, Doris K Hansen, Shambavi Richard, Krina K Patel, Hans C Lee, Ariel Grajales-Cruz Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium , Blood Cancer Journal: 2025


Xinhe Shan, Rowan Kuiper, Chuling Ding, Pashna N Munshi, Edward A Stadtmauer, Sandra P Susanibar-Adaniya Age-related disparities in treatment and outcomes for newly diagnosed multiple myeloma: a population-based study , Haematologica : 2025


Dima D, Afrough A, Goel U, Grajales-Cruz A, Khouri J, Julian K, Pasvolsky O, Banerjee R, Razzo B, Ferreri CJ, Vazquez Martinez MA, Davis JA, Sannareddy A, Castaneda Puglianini O, Raza S, Portuguese AJ, Gaballa MR, Rana M, Lieberman-Cribbin A, DeJarnette S, Gonzalez R, Chen A, Herr MM, Mikkilineni L, Hosoya H, Ouchveridze E, Kaur G, Rossi AC, Shune L, Anwer F, Lin Y, Richard S, Sborov DW, Baz RC, Garfall A, Lee HC, Anderson LD Jr, Cowan AJ, Patel KK, Voorhees PM, Sidana S, Hansen DK, Atrash S, Susanibar-Adaniya SP. Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal Impairment , Blood Advances: 2025